Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Eli Lilly (NYSE: LLY) has announced upcoming presentations of preclinical data at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30. The company will showcase two key developments:
1. LY4050784: A selective SMARCA2 inhibitor, developed in collaboration with Foghorn Therapeutics, showing synergistic activity when combined with chemotherapy, pembrolizumab, and KRAS inhibitors in SMARCA4 mutant cancers.
2. LY4066434: A pan-KRAS inhibitor demonstrating high selectivity over HRAS and NRAS, with robust anti-tumor activity in KRAS-mutant models, including in the CNS.
Both programs are currently in Phase 1 clinical trials.
Eli Lilly (NYSE: LLY) ha annunciato le prossime presentazioni di dati preclinici al 2025 American Association for Cancer Research (AACR) Annual Meeting che si terrà a Chicago dal 25 al 30 aprile. L'azienda presenterà due sviluppi chiave:
1. LY4050784: Un inibitore selettivo di SMARCA2, sviluppato in collaborazione con Foghorn Therapeutics, che mostra un'attività sinergica quando combinato con chemioterapia, pembrolizumab e inibitori di KRAS nei tumori mutanti di SMARCA4.
2. LY4066434: Un inibitore pan-KRAS che dimostra alta selettività su HRAS e NRAS, con una robusta attività antitumorale in modelli mutanti di KRAS, inclusi quelli del sistema nervoso centrale.
Entrambi i programmi sono attualmente in fase di sperimentazione clinica di Fase 1.
Eli Lilly (NYSE: LLY) ha anunciado próximas presentaciones de datos preclínicos en la Reunión Anual de la Asociación Americana para la Investigación del Cáncer (AACR) 2025 en Chicago del 25 al 30 de abril. La compañía presentará dos desarrollos clave:
1. LY4050784: Un inhibidor selectivo de SMARCA2, desarrollado en colaboración con Foghorn Therapeutics, que muestra actividad sinérgica cuando se combina con quimioterapia, pembrolizumab e inhibidores de KRAS en cánceres mutantes de SMARCA4.
2. LY4066434: Un inhibidor pan-KRAS que demuestra alta selectividad sobre HRAS y NRAS, con una robusta actividad antitumoral en modelos mutantes de KRAS, incluidos en el sistema nervioso central.
Ambos programas se encuentran actualmente en ensayos clínicos de Fase 1.
엘리 릴리 (NYSE: LLY)는 2025 미국 암 연구 협회(AACR) 연례 회의에서 시카고에서 4월 25일부터 30일까지 진행될 예정인 전임상 데이터 발표를 알렸습니다. 회사는 두 가지 주요 개발 사항을 소개할 예정입니다:
1. LY4050784: Foghorn Therapeutics와 협력하여 개발된 선택적 SMARCA2 억제제로, SMARCA4 변이 암에서 화학요법, pembrolizumab 및 KRAS 억제제와 결합할 때 시너지 효과를 보입니다.
2. LY4066434: HRAS 및 NRAS에 대한 높은 선택성을 보여주며, KRAS 변이 모델에서 강력한 항종양 활성을 나타내는 범-KRAS 억제제입니다. CNS에서도 효과적입니다.
두 프로그램 모두 현재 1상 임상 시험 중입니다.
Eli Lilly (NYSE: LLY) a annoncé des présentations à venir de données précliniques lors de la Réunion Annuelle de l'Association Américaine pour la Recherche sur le Cancer (AACR) 2025 à Chicago du 25 au 30 avril. L'entreprise mettra en avant deux développements clés :
1. LY4050784 : Un inhibiteur sélectif de SMARCA2, développé en collaboration avec Foghorn Therapeutics, montrant une activité synergique lorsqu'il est combiné avec la chimiothérapie, le pembrolizumab et les inhibiteurs de KRAS dans les cancers mutés de SMARCA4.
2. LY4066434 : Un inhibiteur pan-KRAS démontrant une forte sélectivité sur HRAS et NRAS, avec une activité antitumorale robuste dans des modèles mutés de KRAS, y compris dans le système nerveux central.
Les deux programmes sont actuellement en essais cliniques de Phase 1.
Eli Lilly (NYSE: LLY) hat kommende Präsentationen von präklinischen Daten auf dem 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago vom 25. bis 30. April angekündigt. Das Unternehmen wird zwei wichtige Entwicklungen vorstellen:
1. LY4050784: Ein selektiver SMARCA2-Inhibitor, der in Zusammenarbeit mit Foghorn Therapeutics entwickelt wurde und synergistische Aktivitäten zeigt, wenn er mit Chemotherapie, Pembrolizumab und KRAS-Inhibitoren bei SMARCA4-mutierten Krebserkrankungen kombiniert wird.
2. LY4066434: Ein pan-KRAS-Inhibitor, der eine hohe Selektivität gegenüber HRAS und NRAS aufweist und in KRAS-mutierten Modellen, einschließlich im ZNS, eine robuste antitumorale Aktivität zeigt.
Beide Programme befinden sich derzeit in klinischen Studien der Phase 1.
- Two promising cancer drug candidates in Phase 1 trials
- Strategic collaboration with Foghorn Therapeutics for SMARCA2 inhibitor development
- LY4066434 shows effectiveness in CNS applications, expanding potential market reach
- Both drugs still in early Phase 1 trials, far from commercialization
- Only preclinical data available, no human trial results yet
In an oral presentation, Lilly, in collaboration with Foghorn Therapeutics, will present new preclinical data for LY4050784, a selective inhibitor of SMARCA2, in combination with chemotherapy, pembrolizumab, and KRAS inhibitors in preclinical models of SMARCA4 mutant cancers. Preclinical data for LY4066434, a pan-KRAS inhibitor that is highly selective over HRAS and NRAS, will also be presented. Both programs are currently enrolling Phase 1 studies.
Details on presentations are below:
Presentation Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors
Abstract Number: 3779
Session Date & Time: Monday, April 28, 2:30-4:30 p.m. CST
Session Title: Continuum of Innovation: Biological Therapeutic Agents
Presenter: Nathan Brooks
Presentation Title: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS
Abstract Number: 4375
Session Date & Time: Tuesday, April 29, 9 a.m.-12 p.m. CST
Session Title: RAS Inhibitors
Presenter: Hong Gao
For more information on Lilly's Oncology pipeline click here.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly's oncology pipeline, including therapies under development, and the timeline for future readouts, presentations, and other milestones relating to therapies under development and their clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, or that any of these therapies will receive initial regulatory approval or approvals for additional indications, as applicable, or be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: | Megan Talon; megan.talon@lilly.com; 463-209-1470 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-details-of-presentations-at-2025-american-association-for-cancer-research-aacr-annual-meeting-302409875.html
SOURCE Eli Lilly and Company
FAQ
What new cancer treatments will Eli Lilly (LLY) present at AACR 2025?
How does Eli Lilly's (LLY) new SMARCA2 inhibitor LY4050784 work in cancer treatment?
What are the key features of Eli Lilly's (LLY) new pan-KRAS inhibitor LY4066434?
When and where will Eli Lilly (LLY) present its cancer research at AACR 2025?
